Lansforsakringar Fondforvaltning AB publ Makes New $29.66 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lansforsakringar Fondforvaltning AB publ purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 41,633 shares of the biopharmaceutical company's stock, valued at approximately $29,656,000.

Several other large investors also recently made changes to their positions in REGN. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the period. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 18.5%

Shares of REGN traded down $112.15 during trading hours on Friday, hitting $493.24. 6,307,887 shares of the stock were exchanged, compared to its average volume of 829,463. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $485.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business has a 50-day moving average of $584.25 and a 200-day moving average of $665.66. The firm has a market capitalization of $53.25 billion, a P/E ratio of 12.89, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the company earned $9.55 earnings per share. The company's quarterly revenue was down 3.7% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.71%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Analysts Set New Price Targets

A number of research firms recently commented on REGN. Citigroup upgraded shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the company from $600.00 to $700.00 in a research note on Wednesday, May 14th. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Bank of America lowered their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective on the stock. Finally, UBS Group lowered their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $874.56.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.